Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced an agreement with a leading group purchasing organization (GPO) that will provide coverage for TONMYA (cyclobenzaprine HCl sublingual tablets) to approximately 35 million U.S. commercial lives, representing about 20% of the commercial market. The agreement, effective May 1, 2026, includes standard utilization management criteria and marks a key milestone in the company's efforts to broaden patient access to its recently approved non-opioid fibromyalgia treatment.
TONMYA, the first new treatment for fibromyalgia in more than 15 years, was approved by the U.S. Food and Drug Administration (FDA) and is the flagship medicine of Tonix Pharmaceuticals. The company is focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The GPO agreement is part of a broader strategy to secure coverage across commercial and government channels. Tonix already has Medicaid coverage in 38 states, representing approximately 55 million lives.
The importance of this agreement lies in its potential to significantly increase patient access to TONMYA, offering a non-opioid alternative for managing fibromyalgia, a chronic condition characterized by widespread pain, fatigue, and cognitive issues. With the opioid crisis continuing to impact public health, expanding access to non-opioid pain management options is critical. The coverage of 35 million commercial lives could lead to broader adoption of TONMYA among healthcare providers and patients, potentially reducing reliance on opioids for fibromyalgia management.
Tonix Pharmaceuticals is also advancing its CNS pipeline beyond fibromyalgia. The company is conducting Phase 2 clinical trials to evaluate TONMYA's potential in major depressive disorder and acute stress disorder. Additionally, its CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare genetic disorder. In the immunology space, Tonix is developing monoclonal antibodies TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
The GPO agreement is a strategic win for Tonix as it continues to build commercial infrastructure. The company already markets acute migraine products Zembrace SymTouch and Tosymra. With this new coverage, Tonix aims to leverage its sales force and distribution network to maximize TONMYA's market penetration. For investors, this development signals progress in commercial execution and potential revenue growth. The full press release is available at https://ibn.fm/ShicX. For more information about Tonix Pharmaceuticals, visit their newsroom at https://ibn.fm/TNXP.
